Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Review ArticleClinical Review

Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians

Richa Sood, Lynne Shuster, Robin Smith, Ann Vincent and Aminah Jatoi
The Journal of the American Board of Family Medicine March 2011, 24 (2) 202-210; DOI: https://doi.org/10.3122/jabfm.2011.02.100194
Richa Sood
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynne Shuster
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Smith
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Vincent
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aminah Jatoi
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Greendale GA,
    2. Lee NP,
    3. Arriola ER
    . The menopause. Lancet 1999;353:571–80.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Santen RJ,
    2. Allred DC,
    3. Ardoin SP,
    4. et al
    . Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1–s66.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Hulley S,
    2. Grady D,
    3. Bush T,
    4. et al
    . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Viscoli CM,
    2. Brass LM,
    3. Kernan WN,
    4. Sarrel PM,
    5. Suissa S,
    6. Horwitz RI
    . A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243–9.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Rossouw JE,
    2. Anderson GL,
    3. Prentice RL,
    4. et al
    . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    ACOG Committee of Gynecologic Practice. Committee opinion #322: compounded bioidentical hormones Obstet Gynecol 2005;106(5 Pt 1):1139–40.
  8. 8.↵
    1. Taylor M
    . Unconventional estrogens: estriol, biest, and triest. Clin Obstet Gynecol 2001;44:864–79.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Lethaby AE,
    2. Brown J,
    3. Marjoribanks J,
    4. Kronenberg F,
    5. Roberts H,
    6. Eden J
    . Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395.
  10. 10.↵
    1. Utian WH,
    2. Archer DF,
    3. Bachmann GA,
    4. et al
    . Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–602.
    OpenUrlPubMedWeb of Science
  11. 11.↵
    US Department of Health & Human Services, Food and Drug Administration. For consumers. Bio-identicals: sorting myths from facts. Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049311.htm. Accessed January 18, 2011.
  12. 12.↵
    The North American Menopause Society. Hormone products for postmenopausal use in the United States and Canada. Available from: http://www.menopause.org/htcharts.pdf. Accessed January 18, 2011.
  13. 13.↵
    US Department of Health & Human Services, Food and Drug Administration. Importation of active pharmaceutical ingredients (APIs) requirements CPG 460.200 pharmacy compounding compliance policy guides manual (tab M). Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM118050.pdf. Accessed January 18, 2011.
  14. 14.↵
    US Pharmacopeial Convention, Council of the Convention Section on the Quality of Compounded Medicine. White paper: a model system to promote access to good quality compounded medicines. Available from: http://www.usp.org/pdf/EN/members/goodMedicine.pdf. Accessed January 18, 2011.
  15. 15.↵
    US Pharmacopeial Convention, Council of the Convention Section on the Quality of Compounded Medicine. White paper: USP's role in setting enforceable quality standards for medicines. Available from: http://www.usp.org/pdf/EN/members/qualityMedicines.pdf. Accessed January 18, 2011.
  16. 16.↵
    Food and Drug Administration Office of Women's Health. FDA takes action against compounded menopause hormone therapy drugs. Available from: http://orwh.od.nih.gov/FDA_ActionHormoneTherapyDrugs.html. Accessed June 25, 2009.
  17. 17.↵
    1. Chervenak J
    . Bioidentical hormones for maturing women. Maturitas 2009;64:86–9.
    OpenUrlPubMed
  18. 18.↵
    US Department of Health & Human Services, Food and Drug Administration. Compounded menopausal hormone therapy questions and answers. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm183088.htm. Accessed January 18, 2011.
  19. 19.↵
    1. Boothby LA,
    2. Doering PL,
    3. Kipersztok S
    . Bioidentical hormone therapy: a review. Menopause 2004;11:356–67.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Vining RF,
    2. McGinley RA,
    3. Symons RG
    . Hormones in saliva: mode of entry and consequent implications for clinical interpretation. Clin Chem 1983;29:1752–6.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    US Department of Health & Human Services, Food and Drug Administration. Transcript of FDA press conference on FDA actions on bio-identical hormones. Available from: http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucm122174.pdf. Accessed January 18, 2011.
  22. 22.↵
    1. Kuiper GG,
    2. Carlsson B,
    3. Grandien K,
    4. et al
    . Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863–70.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Eckler K
    . Are all estrogens created equal? Menopause 2004;11:7–8.
    OpenUrlPubMed
  24. 24.↵
    1. Eden JA,
    2. Hacker NF,
    3. Fortune M
    . Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust 2007;187:244–5.
    OpenUrlPubMed
  25. 25.↵
    1. Fitzpatrick LA,
    2. Good A
    . Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 1999;72:389–97.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Barrett-Connor E,
    2. Slone S,
    3. Greendale G,
    4. et al
    . The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997;27:261–74.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Montplaisir J,
    2. Lorrain J,
    3. Denesle R,
    4. Petit D
    . Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001;8:10–6.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. de Lignieres B
    . Oral micronized progesterone. Clin Ther 1999;21:41–60, discussion 1–2.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Sitruk-Ware R,
    2. Bricaire C,
    3. De Lignieres B,
    4. Yaneva H,
    5. Mauvais-Jarvis P
    . Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications–a review. Contraception 1987;36:373–402.
    OpenUrlPubMed
  30. 30.↵
    1. Anderson GL,
    2. Limacher M,
    3. Assaf AR,
    4. et al
    . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Fournier A,
    2. Berrino F,
    3. Clavel-Chapelon F
    . Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Lewis JG,
    2. McGill H,
    3. Patton VM,
    4. Elder PA
    . Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2002;41:1–6.
    OpenUrlPubMed
  33. 33.↵
    1. Kocis P
    . Prasterone. Am J Health Syst Pharm 2006;63:2201–10.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Panjari M,
    2. Davis SR
    . DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239–48.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Stomati M,
    2. Monteleone P,
    3. Casarosa E,
    4. et al
    . Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14:342–63.
    OpenUrlPubMedWeb of Science
  36. 36.↵
    1. Kritz-Silverstein D,
    2. von Muhlen D,
    3. Laughlin GA,
    4. Bettencourt R
    . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc 2008;56:1292–8.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Raven PW,
    2. Hinson JP
    . Dehydroepiandrosterone (DHEA) and the menopause: an update. Menopause Int 2007;13:75–8.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Kaaks R,
    2. Rinaldi S,
    3. Key TJ,
    4. et al
    . Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071–82.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Bachmann G,
    2. Bancroft J,
    3. Braunstein G,
    4. et al
    . Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002;77:660–5.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Wierman ME,
    2. Basson R,
    3. Davis SR,
    4. et al
    . Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697–710.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Somboonporn W,
    2. Davis S,
    3. Seif MW,
    4. Bell R
    . Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;(4):CD004509.
  42. 42.↵
    1. Bachmann GA
    . The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 2002;77(Suppl 4):S72–6.
    OpenUrlCrossRefPubMed
  43. 43.↵
    North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005;12:496–511; quiz 649.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Davis SR,
    2. McCloud P,
    3. Strauss BJ,
    4. Burger H
    . Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227–36.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Sherwin BB
    . Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord 1988;14:177–87.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Shifren JL,
    2. Braunstein GD,
    3. Simon JA,
    4. et al
    . Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–8.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Shufelt CL,
    2. Braunstein GD
    . Safety of testosterone use in women. Maturitas 2009;63:63–6.
    OpenUrlPubMed
  48. 48.↵
    1. Nippoldt TB
    Mayo Clinic. Addison's disease. Is there such a thing as adrenal fatigue? Available from: http://www.mayoclinic.com/health/adrenal-fatigue/AN01583. Accessed January 18, 2011.
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 24 (2)
The Journal of the American Board of Family Medicine
Vol. 24, Issue 2
March-April 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians
Richa Sood, Lynne Shuster, Robin Smith, Ann Vincent, Aminah Jatoi
The Journal of the American Board of Family Medicine Mar 2011, 24 (2) 202-210; DOI: 10.3122/jabfm.2011.02.100194

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Counseling Postmenopausal Women about Bioidentical Hormones: Ten Discussion Points for Practicing Physicians
Richa Sood, Lynne Shuster, Robin Smith, Ann Vincent, Aminah Jatoi
The Journal of the American Board of Family Medicine Mar 2011, 24 (2) 202-210; DOI: 10.3122/jabfm.2011.02.100194
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Discussion Point 1: “Bioidentical” Does Not Mean “Natural”
    • Discussion Point 2: “Custom-Compounded HT” is Not Synonymous with “BHT”
    • Discussion Point #3: FDA-Approved Products Offer Certain Advantages Over Custom-Compounded Preparations
    • Discussion Point 4: The Concept of an “Absolutely Safe” Hormone is a Myth
    • Discussion Point 5: CHT is a Broad Term That Includes Both Bioidentical and Nonbioidentical Hormones
    • Discussion Point 6: Benefits of “Individualization” and Monitoring with Testing Hormone Levels Have Not Been Established
    • Discussion Point 7: Estriol is a Weak Estrogen But Not Necessarily a Benign Estrogen
    • Discussion Point 8: Bioidentical Progesterone and Synthetic Progestins Are Structurally Dissimilar and Functionally Different in Nonendometrial Tissues
    • Discussion Point 9: The Use of DHEA and Testosterone Therapy among Women is Controversial
    • Discussion Point 10: Adrenal Fatigue Does Not Mean Adrenal Insufficiency
    • Conclusions
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Content Usage and the Most Frequently Read Articles by Issue in 2011
  • Google Scholar

More in this TOC Section

  • Interpretating Normal Values and Reference Ranges for Laboratory Tests
  • Non-Surgical Management of Urinary Incontinence
  • Screening and Diagnosis of Type 2 Diabetes in Sickle Cell Disease
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire